Is BioAtla, Inc. (BCAB) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 6.7% / 30% | 393.6% / 30% | 0.0% / 30% | 30.63% / 5% | ✗ NOT HALAL |
| DJIM | 6.7% / 33% | 393.6% / 33% | 0.0% / 33% | 30.63% / 5% | ✗ NOT HALAL |
| MSCI | 1.6% / 33% | 93.6% / 33% | 0.0% / 33% | 30.63% / 5% | ✗ NOT HALAL |
| S&P | 6.7% / 33% | 393.6% / 33% | 0.0% / 33% | 30.63% / 5% | ✗ NOT HALAL |
| FTSE | 1.6% / 33% | 93.6% / 33% | 0.0% / 50% | 30.63% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -105.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$72M |
| Free Cash Flow | -$72M |
| Total Debt | $836,000 |
| Current Ratio | 0.5 |
| Total Assets | $52M |
Price & Trading
| Last Close | $0.17 |
| 50-Day MA | $0.21 |
| 200-Day MA | $0.49 |
| Avg Volume | 2.5M |
| Beta | 1.1 |
|
52-Week Range
$0.13
| |
About BioAtla, Inc. (BCAB)
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BioAtla, Inc. (BCAB) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BioAtla, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BioAtla, Inc.'s debt ratio?
BioAtla, Inc.'s debt ratio is 6.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.6%.
What are BioAtla, Inc.'s key financial metrics?
BioAtla, Inc. has a market capitalization of $13M, and revenue of $11M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.